Please login to the form below

Not currently logged in
Email:
Password:

Stada

This page shows the latest Stada news and features for those working in and with pharma, biotech and healthcare.

Takeda divests over-the-counter and prescription drugs to Stada for $660m

Takeda divests over-the-counter and prescription drugs to Stada for $660m

Japanese drug-maker Takeda has entered an agreement with German pharma Stada to divest a portfolio of select over-the-counter (OTC) and prescription drugs for a total value of $660m. . ... The portfolio of products to be divested to Stada and Acino

Latest news

  • Post-merger Celgene to lead pharma growth Post-merger Celgene to lead pharma growth

    Behind Celgene is a cohort of five companies which are expected to post profit growth of 6-10%: AbbVie, AstraZeneca, Eli Lilly, Stada and Takeda.

  • Stada's €4.1bn takeover goes through Stada's €4.1bn takeover goes through

    German pharma company finally comes under new ownership. After months of wrangling, German pharma company Stada has finally come under new ownership after a successful tender by private equity firms Bain ... The buyout - which is the largest for a

  • Time running out on new Stada takeover bid Time running out on new Stada takeover bid

    Only 34% of shareholders have backed the deal so far. With a deadline looming on Wednesday, only a third of shareholders in German pharma company Stada have accepted the takeover bid ... As of Friday around 34% of Stada's shareholders had accepted, well

  • Trouble at the top of Stada as Bain and Cinven mull fresh bid Trouble at the top of Stada as Bain and Cinven mull fresh bid

    The chief executive and finance chief of Stada have stepped down in the wake of the failed takeover by private equity firms Bain and Cinven, citing "personal reasons". ... Tjeenk Willink said his first priorities will be to "continue to implement Stada's

  • No deal for Stada as private equity takeover bid collapses No deal for Stada as private equity takeover bid collapses

    66 per share deal which would have valued Stada at around 5.3bn including debt. ... Stada's board had lent its support to the Bain-Cinven offer over a rival 58 per share bid from Advent and Permira.

More from news
Approximately 10 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Deal Watch - May 2017 Deal Watch - May 2017

    Given this background what do we make of the deal where two private equity companies, Bain and Cinven, joined forces to acquire Stada for $5.63bn? ... So why did Bain/Cinven acquire Stada at a high price? Almost certainly it was because they were in

  • Deal Watch February 2017 Deal Watch February 2017

    What is more than rumour, is the interest from several parties in acquiring the German generic company, Stada, which has pan-European capabilities and a foothold in Russia. ... Whatever happens to Stada this represents another chapter in the evolution of

  • Deal Watch table for August 2013 Deal Watch table for August 2013

    485. OptiMedica  /. Abbott. Acquisition. Ophthalmic device company. 400. Thornton &Ross /. Stada Arzneimittel. Acquisition. OTC manufacturer. 345. Endosense  /. St Jude Medical.

  • Pharma deals during August 2013 Pharma deals during August 2013

    Generics business consolidation was also evident on this side of the pond. In a defensive move the German drugmaker Stada Arzneimittel announced the $345m take-over of the UK OTC company, ... Thornton &Ross.Thornton &Ross is one of the fastest growing

  • Pharma deals during November 2012 Pharma deals during November 2012

    the subject of interest from companies such as GSK and Stada for some time. It is currently majority owned by Russia's largest drugstore chain “36.6” and has enjoyed 20

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

  • Britannia promotes Robert Wood Britannia promotes Robert Wood

    Prior to joining Britannia, which is part of Stada, in early 2011, his roles included business unit director, pharmaceuticals at International SOS and vice president of business development at Optasia Medical.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...

Infographics